Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Interest Coverage Ratio (2010 - 2026)

Kura Oncology (KURA) reported Interest Coverage Ratio of 234.57 for Q1 2026, down 38.49% year-over-year from 381.37 in Q1 2025, and down 141.03% on a QoQ basis from 571.64 in Q4 2025.

Kura Oncology (KURA) has 8 years of Interest Coverage Ratio data on file, last reported at 234.57 in Q1 2026.

  • Quarterly Interest Coverage Ratio fell 38.49% year-over-year to 234.57 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.97 (up 87.95% YoY) and the FY2025 annual result came in at 200.81, down 68.28% from the prior year.
  • Interest Coverage Ratio retreated to 234.57 in Q1 2026 per KURA's latest filing, from 571.64 in the prior quarter.
  • Across five years, Interest Coverage Ratio topped out at 571.64 in Q4 2025 and bottomed at 234.57 in Q1 2026.
  • The 3-year median for Interest Coverage Ratio is 131.05 (2024), against an average of 67.6.
  • Peak annual rise in Interest Coverage Ratio reached 1471.58% in 2025, while the deepest fall reached 43.15% in 2025.
  • Tracing KURA's Interest Coverage Ratio over 3 years: stood at 41.68 in 2024, then jumped by 1471.58% to 571.64 in 2025, then tumbled by 141.03% to 234.57 in 2026.
  • Per Business Quant, the three latest KURA Interest Coverage Ratio figures stand at 234.57 (Q1 2026), 571.64 (Q4 2025), and 187.59 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -129.79
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3.58
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -258.33
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - 11.50
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 49.84
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 3.88
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn -234.57

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -234.57
Dec 31, 2025 571.64
Sep 30, 2025 -187.59
Jun 30, 2025 -168.11
Mar 31, 2025 -169.37
Dec 31, 2024 -41.68
Sep 30, 2024 -131.05
Jun 30, 2024 -124.21
Mar 31, 2024 -123.43
Dec 31, 2014 -0.26
Sep 30, 2014 -2.86
Jun 30, 2014 -3.19
Mar 31, 2014 -2.54
Dec 31, 2013 -4.86
Sep 30, 2013 -2.69
Jun 30, 2013 -4.22
Mar 31, 2013 -3.75
Dec 31, 2012 -6.51
Sep 30, 2012 -3.68
Jun 30, 2012 -3.93
Mar 31, 2012 -3.75
Dec 31, 2011 -8.78
Sep 30, 2011 -5.91
Jun 30, 2011 -6.50
Mar 31, 2011 -4.80
Dec 31, 2010 -13.56
Sep 30, 2010 -8.01